Cancer Research Technology Establishes US Subsidiary and Announces Recruitment of Managing Director
London, UK; Boston, USA, 11th April, 2006 - Cancer Research Technology Ltd. (“CRT”), specialists in oncology-focused development and commercialisation, today announced the establishment of Cancer Research Technology Inc. (“CRT Inc.”), a US subsidiary based in Boston and the recruitment of Dr Larry Steranka as Managing Director.
CRT Inc. will provide oncology-focused technology transfer and development expertise to leading US not-for-profit research institutions and represent CRT in licensing discussions with US biopharmaceutical companies. Through partnership with CRT, academic collaborators are able to bridge the fundamental development gap between exploratory research and industrial development of diagnostics and therapeutics in oncology. Development of academic-based cutting edge discoveries will be carried out in conjunction with biotherapeutic and drug discovery groups within CRT’s Development Laboratories.
Dr Keith Blundy, CRT’s COO and CRT Inc.’s Chairman, stated “Through CRT Inc., Dr Steranka will reinforce our strategy of oncology-focused development of diagnostics and therapeutics in partnership with leading US academic institutions. Dr Steranka’s experience, both in industry and academic-based technology transfer, will benefit CRT’s operations on both sides of the Atlantic”.
Prior to joining CRT Inc. as Managing Director, Dr Steranka was the Executive Director of Brandeis University’s Office of Technology Licensing, and immediately before that, an Associate Director for Licensing at Harvard University’s Office of Technology and Trademark Licensing. Dr Steranka has also held senior positions within major pharmaceutical and biotechnology companies.
---ends---
About Cancer Research Technology Ltd.
Cancer Research Technology Limited (“CRT”) is an oncology-focused development and commercialisation company that realises cancer patient benefit from publicly-funded research worldwide. CRT works closely with leading international cancer scientists, their institutes and funding bodies to protect, develop and commercialise oncology-related discoveries. CRT is wholly owned by Cancer Research UK, the largest independent funder of cancer research in the world. Further information about CRT can be found at www.CancerTechnology.com.
About Cancer Research Technology Inc.
Cancer Research Technology Inc. (“CRT Inc.”) is an oncology-focused development and commercialisation company that realises cancer patient benefit from US not-for-profit research. CRT Inc. works closely with leading US cancer scientists and their institutes to protect, develop and commercialise oncology-related discoveries. CRT Inc. is wholly owned by Cancer Research Technology Ltd. Further information about CRT Inc. can be found at www.CancerTechnology.com.
About CRT’s Development Laboratories
CRT’s Development Laboratories are situated within the Wolfson Institute for Biomedical Research at University College London. The laboratories are staffed with industrially trained and experienced scientists with core competences in molecular and cellular biology, assay design and high throughput screening, medicinal chemistry and early pharmacology. CRT’s Development Laboratories develop biotherapeutics and small molecule inhibitors from academic discoveries through to in vivo proof of concept studies prior to out-licensing, thereby facilitating industrial preclinical development.
|
